中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

非酒精性脂肪性肝病药物治疗进展

蒋艳明 施军平

引用本文:
Citation:

非酒精性脂肪性肝病药物治疗进展

详细信息
  • 中图分类号: R575.5

The progress of pharmacotherapy in non-alcoholic fatty liver disease

  • 摘要: 非酒精性脂肪性肝病(NAFLD)是我国肝酶异常和慢性肝病的常见原因之一,其治疗包括控制饮食、运动锻炼和药物治疗。目前,临床上治疗NAFLD的药物包括减肥药、胰岛素增敏剂、抗氧化剂、抑制肾素血管紧张素系统的降压药、调脂药、细胞因子调节剂和具有良好前景的大麻素受体拮抗剂。在此对NAFLD治疗药物的近期发展作一综述。

     

  • [1]Harrison SA, Fecht W, Brunt EM.Orlistat for overweightsubjects with non-alcoholic steat-ohepatitis:A random-ized, prospective trial[J].Hepatology, 2009, 49 (1) :80-86.
    [2]Nar A, Gedik O.The effect of metformin on leptin in obesepatients with type 2 diabetes mellitus and nonalcoholic fattyliver disease[J].Acta Diabetol, 2009, 46 (2) :113-118.
    [3]Raso GM, Esposito E, Iacono A, et al.Comparative thera-peutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat[J].Eur J Phar-macol, 2009, 604 (1-3) :125-131.
    [4]Nobili V, Manco M, Ciampalini P, et al.Metformin use inchildren with nonalcoholic fatty liver disease:an open-label, 24-month, observational pilot study[J].Clin Ther, 2008, 30 (6) :1168-1176.
    [5]Ratziu V, Charlotte F, Bernhardt C, et al.Long-term efficacyof rosiglitazone in nonalcoholic steatohepatitis:results of thefatty liver improvement by rosiglitazone therapy (FLIRT 2) ex-tension trial[J].Hepatology, 2010, 51 (2) :445-453.
    [6]Gastaldelli A, Harrison SA, Belfort-Aguilar R, et al.Impor-tance of changes in adipose tissue insulin resistance to histo-logical response during thiazolidinedione treatment of patientswith nonalcoholic steatohepatitis[J].Hepatology, 2009, 50 (4) :1087-1093.
    [7]Harrison SA.Thiazolidinedione therapy for Nonalcoholic Steato-hepatitis:Go, Stop, or Proceed with Caution?[J].Hepatolo-gy, 2010, 51 (2) :366-369.
    [8]Sanyal AJ, Chalasani N, Kowdley KV, et al.Pioglitazone, Vi-tamin E, or Placebo for Nonalc-oholic Steatohepatitis[J].N Engl J Med, 2010, 362 (18) :1675-1685.
    [9]Mine T, Miura K, KajiokaT, et al.Nateglinide prevents fattyliver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat diet[J].Metabolism, 2008, 57 (1) :140-148.
    [10]Rosselli MS, Burgue n~o AL, Carabelli J, et al.Losartan re-duces liver expression of plasmi-nogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liverdisease model[J].Atherosclerosis, 2009, 206 (1) :119-126.
    [11]Yoshiji H, Noguchi R, Ikenaka Y, et al.Losartan, an angio-tensin-II type 1 receptor blocker, attenuates the liver fibro-sis development of non-alcoholic steatohepatitis in the rat[J].BMC Res Notes, 2009, 2:70.
    [12]Fabbrini E, Mohammed BS, Korenblat KM, et al.Effect offenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoproteins kinetics, and insulin action inobese subjects with nonalcoholic fatty liver disease[J].ClinEndocrinol Metab, 2010, 95 (6) :2727-2735.
    [13]Kondo K, SugiokaT, TsukadaK, et al.Fenofibrate, aperoxi-some proliferator-activated receptor alpha agonist, im-proves hepatic microcirculatory patency and oxygen availabili-ty in a high-fat-diet-induced fatty liver in mice[J].AdvExp Med Biol, 2010, 662:77-82.
    [14]Matafome P, Nunes E, Louro T, et al.A role for atorvastatinand insulin combination in pro-tecting from liver injury in amodelof type2 diabetes with hyperlipidemia[J].Naunyn Schmi-edebergs Arch Pharmacol, 2009, 379 (3) :241-251.
    [15]Nobili V, Manco M, Devito R.Lifestyle intervention and an-tioxidant therapy in children with nonalcoholic fatty liver dis-ease:a randomized, controlled trial[J].Hepatology, 2008, 48 (1) :119-128.
    [16]Lee YM, Sutedja DS, Wai CT, et al.A randomized con-trolled pilot study of Pentoxifyllinein patients with non-alco-holic steatohepatitis (NASH) [J].Hepatol Int, 2008, 2 (2) :196-201.
    [17]Abdelmalek MF, Sanderson SO, Angulo P, et al.Betaine fornonalcoholic fatty liver disease:results of a randomized pla-cebo-controlled trial[J].Hepatology, 2009, 50 (6) :1818-1826.
    [18]Wu X, Zhang L, Gurley E, et al.Prevention of free fatty acid-induced hepatic lipotoxicity by 18 beta-glycyrrhetinic acidthrough lysosomal and mitochondrial pathways[J].Hepatol-ogy, 2008, 47 (6) :1905-1915.
    [19]Tsujimoto T, Kawaratani H, KitazawaT, et al.Immunothera-py for nonalcoholic steato-hepatitis using the multiple cyto-kine production modulator Y-40138[J].World J Gastroen-terol, 2009, 15 (44) :5533-5540.
    [20]中华医学会肝病学会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南 (2010年修订版) [J].中华肝脏病杂志, 2010, 18 (3) :163-166.
    [21]Purohit V, RapakaR, Shurtleff D.Role of cannabinoids in thedevelopment of fatty liver (steatosis) [J].AAPS J, 2010, 12 (2) :233-237.
    [22]Vemuri VK, Janero DR, Makriyannis A.Pharmaco therapeu-tic targeting of the endocannab-inoid signaling system:drugs for obesity and the metabolic syndrome[J].PhysiolBehav, 2008, 93 (4-5) :671-686.
    [23]Gary-Bobo M, Elachouri G, Gallas JF, et al.Rimonabantreduces obesity-associated hepatic steatosis and featuresof metabolic syndrome in obese Zucker fa/farats[J].Hepa-tology, 2007, 46 (1) :122-129.
    [24]Mallat A, Lotersztajn S.Endocannabinoids and their role infatty liver disease[J].Dig Dis, 2010, 28 (1) :261-266.
  • 加载中
计量
  • 文章访问数:  3371
  • HTML全文浏览量:  8
  • PDF下载量:  766
  • 被引次数: 0
出版历程
  • 出版日期:  2011-09-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回